Alnylam Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $4.2 million on Aug 20 ’24. In the deal valued at $280.00 per share,15,000 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 73,441 shares worth roughly $17.3 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Greenstreet Yvonne bought 15,000 shares, generating $4,200,000 in total proceeds.
Before that, Fitzgerald Kevin Joseph sold 22,025 shares. Alnylam Pharmaceuticals Inc shares valued at $5,968,516 were divested by the CSO & EVP, Head of Research at a price of $270.99 per share. As a result of the transaction, Fitzgerald Kevin Joseph now holds 12,881 shares, worth roughly $3.03 million.
Wolfe Research downgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Underperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Goldman also remained covering ALNY and has increased its forecast on August 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Goldman revised its rating on February 16, 2024. It rated ALNY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALNY
On Friday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -8.67% to $235.56. Over the last five days, the stock has lost -15.09%. Alnylam Pharmaceuticals Inc shares have risen nearly 23.07% since the year began. Nevertheless, the stocks have risen 37.71% over the past one year. While a 52-week high of $304.39 was reached on 10/17/24, a 52-week low of $141.98 was recorded on 04/25/24. SMA at 50 days reached $274.95, while 200 days put it at $210.51.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 228.90, which if violated will result in even more drops to 222.25. On the upside, there is a resistance level at 248.19. A further resistance level may holdings at 260.83. The Relative Strength Index (RSI) on the 14-day chart is 27.06, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -16.70, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.72%. Stochastics %K at 2.61% indicates the stock is a buying.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2024-10-31, dropping by -0.81 million shares to a total of 3.7 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 4.51 million shares. There was a decline of -21.91%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
